Biogen Inc. (Nasdaq: BIIB)’s Chief Executive Officer is searching for smaller deals to expand its treatment portfolio as the company prepares for a future that he expects will be highly dependent on Alzheimer’s disease drugs.
To read the entire story, you must be logged in.
Please log in now or register with us.
